Olmesartan medoxomil (OLM) plus amlodipine (AML) improves BP goal attainment in moderate-to-severe hypertensive patients not adequately controlled with AML monotherapy

被引：0

作者：

Volpe, M. ^{[1
]}

Laeis, P. ^{[2
]}

Ammentorp, B. ^{[2
]}

Haag, U. ^{[3
]}

机构：

[1] Univ Rome, Div Cardiol, Rome, Italy

[2] Daiichi Sankyo Europe GmbH, Munich, Germany

[3] HaaPACS GmbH, Schriesheim, Germany

来源：

JOURNAL OF HYPERTENSION | 2008年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

引用

页码：S473 / S473

页数：1

共 36 条

[1] Olmesartan medoxomil (OLM) plus amlodipine (AML) provides BP-lowering efficacy in moderate-to-severe hypertensive patients (pts) not adequately controlled with AML monotherapy
Volpe, M.
Laeis, P.
Ammentorp, B.
Haag, U.
JOURNAL OF HYPERTENSION, 2008, 26 : S473 - S473
[2] Olmesartan medoxomil (OLM) plus amlodipine (AML) provides BP reduction and improves BP goal rate attainment in patients (pts) with moderate-to-severe hypertension
Barrios, V.
Laies, P.
Ammentorp, B.
Haag, U.
Calderon, A.
Escobar, C.
JOURNAL OF HYPERTENSION, 2008, 26 : S472 - S473
[3] EFFICACY OF OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) PLUS AMLODIPINE (AML) IN AGE DEFINED SUBGROUPS OF MODERATE-TO-SEVERE HYPERTENSIVE PATIENTS
De La Sierra, A.
JOURNAL OF HYPERTENSION, 2009, 27 : S131 - S131
[4] OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) IMPROVES BLOOD PRESSURE (BP) CONTROL THROUGHOUT 24 HOURS COMPARED WITH AML MONOTHERAPY IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION
Parati, G.
Bilo, G.
JOURNAL OF HYPERTENSION, 2010, 28 : E111 - E111
[5] BLOOD PRESSURE (BP) THRESHOLD ATTAINMENT WITH OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) IN PATIENTS WITH MODERATE TO SEVERE HYPERTENSION
Burnier, M.
Mourad, J-J.
Koch, W.
JOURNAL OF HYPERTENSION, 2009, 27 : S281 - S282
[6] Olmesartan medoxomil (OLM) plus amlodipine (AML) is well-tolerated in patients with moderate-to-severe hypertension
Brommer, P.
Laeis, P.
Ammentorp, B.
Haag, U.
JOURNAL OF HYPERTENSION, 2008, 26 : S473 - S473
[7] EFFICACY AND TOLERABILITY OF OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) BY BASELINE HYPERTENSION SEVERITY SUBGROUP IN PATIENTS WITH MODERATE TO SEVERE HYPERTENSION
Laeis, P.
Ammentorp, B.
JOURNAL OF HYPERTENSION, 2009, 27 : S432 - S432
[8] OLMESARTAN MEDOXOMIL/AMLODIPINE (OLM/AML) PROVIDES 24-HOUR ANTIHYPERTENSIVE EFFICACY - ADDITIONAL EFFECT BY UPTITRATION IN PATIENTS WITH MODERATE-TO-SEVERE HYPERTENSION
Heagerty, A. M.
Laeis, P.
Haag, U.
JOURNAL OF HYPERTENSION, 2009, 27 : S283 - S283
[9] AN AMLODIPINE (AML) plus OLMESARTAN MEDOXOMIL (OM)-BASED TREATMENT ALGORITHM ACHIEVES BP CONTROL IN A RANGE OF HYPERTENSIVE PATIENTS, REGARDLESS OF THE TYPE OF PREVIOUS ANTIHYPERTENSIVE MONOTHERAPY
Neutel, J. M.
Nesbitt, S. D.
Waverczak, W. F.
Qian, C.
Shojaee, A.
ETHNICITY & DISEASE, 2010, 20 (04) : S314 - S314
[10] EFFECTS ON BP CONTROL OF AMLODIPINE (AML)/OLMESARTAN MEDOXOMIL (OM), WITH OR WITHOUT HYDROCHLOROTHIAZIDE (HCTZ), IN BLACK, HISPANIC, AND ASIAN PATIENTS NOT CONTROLLED BY PRIOR ANTI HYPERTENSIVE MONOTHERAPY
Weir, M. R.
Nesbitt, S. D.
Weber, M.
Shojaee, A.
Waverczak, W. F.
Qian, C.
ETHNICITY & DISEASE, 2010, 20 (04) : S312 - S312

← 1 2 3 4 →